文献速递血脂与心血管预防高血压

百万心脏心血管病风险降低模型对启动和强化药物治疗的影响:随机临床试验的预设二次分析

Effect of the Million Hearts Cardiovascular Disease Risk Reduction Model on Initiating and Intensifying Medications: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2021-01-01

干预组高危患者启动或强化率37.3% vs 对照组32.4%(调整差值4.8个百分点,95%CI 2.9-6.7,P<.001),中危患者亦较高(27.9% vs 24.8%,调整差值3.1,95%CI 1.9-4.3,P<.001);约1年后LDL-C和收缩压降幅较小。

要点

  • 按绩效付费模型使高危患者启动或强化降压药或他汀的比例提高4.8个百分点。
  • 中危患者虽未获付费,启动或强化率亦提高3.1个百分点。
  • 约1年后干预组LDL-C和收缩压降幅较小,临床意义有限。

核心结论

  • 按绩效付费模型在基线用药率已较高的情况下,仅适度增加了心血管病药物的使用。

研究设计与样本

  • 预设二次分析,采用整群随机实用性试验设计,纳入美国330家初级保健和心内科诊所、健康中心及医院门诊部。

主要发现

  • 高危干预组启动或强化他汀或降压药的比例为37.3%(8127例),对照组为32.4%(4753例),调整差值4.8个百分点(95%CI 2.9-6.7,P<.001)。
  • 约1年后高危干预组LDL-C平均89 mg/dL vs 对照组91 mg/dL,调整差值-1.8个百分点(95%CI -2.9至-0.6,P=.002)。
  • 约1年后高危干预组收缩压平均133 mm Hg vs 对照组135 mm Hg,调整差值-1.7个百分点(95%CI -2.8至-0.6,P=.003)。

临床怎么用

  • 按绩效付费干预可适度促进高危和中危患者启动或强化降压药或他汀,但效应量有限。
  • 在基线用药率已较高的体系中,该模型对血压和LDL-C的额外改善幅度较小。

局限性

  • 临床数据(LDL-C和收缩压)仅覆盖51%的高危入组者。
  • 主要结局(首次心肌梗死和卒中发生率)因试验正在进行而未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The Million Hearts Cardiovascular Disease (CVD) Risk Reduction Model pays provider organizations for measuring and reducing Medicare patients' cardiovascular risk. OBJECTIVE: To assess whether the model increases the initiation or intensification of antihypertensive medications or statins among patients with blood pressure or low-density lipoprotein (LDL) cholesterol levels above guideline thresholds for treatment intensification. DESIGN, SETTING, AND PARTICIPANTS: This prespecified secondary analysis of a cluster-randomized, pragmatic trial included primary care and cardiology practices, health care centers, and hospital-based outpatient departments across the US. Participants included Medicare patients who were enrolled into the model in 2017 by participating organizations and who were at high risk and at medium risk of a myocardial infarction or stroke in 10 years. Patient outcomes were analyzed for 1 year postenrollment (through December 2018) using an intent-to-treat design. Analysis began November 2019. INTERVENTIONS: US Centers for Medicare & Medicaid Services paid organizations for risk stratifying Medicare patients and reducing CVD risk among high-risk patients through discussing risk scores, developing individualized risk reduction plans, and following up with patients twice yearly. MAIN OUTCOMES AND MEASURES: Initiating or intensifying statin or antihypertensive therapy within 1 year of enrollment, measured in Medicare Part D claims, and LDL cholesterol and systolic blood pressure levels approximately 1 year after enrollment, measured in usual care and reported to Centers for Medicare & Medicaid Services via a data registry (data complete for 51% of high-risk enrollees). The study's primary outcome (incidence of first-time myocardial infarction and stroke) is not reported because the trial is ongoing. RESULTS: A total of 330 primary care and cardiology practices, health care centers, and hospital-based outpatient departments and 125 436 Medicare patients were included in this analysis. High-risk patients in the intervention group had a mean (SD) age of 74 (4.1), 15 213 (63%) were male, 21 657 (90%) were receiving antihypertensive medication at baseline, and 16 558 (69%) were receiving statins. Almost all (21 791 [91%]) high-risk intervention group patients had above-threshold systolic blood pressure level (>130 mm Hg), LDL cholesterol level (>70 mg/dL), or both. Patients in the intervention group with these risk factors were more likely than control patients (8127 [37.3%] vs 4753 [32.4%]; adjusted difference in percentage points, 4.8; 95% CI, 2.9-6.7; P < .001) to initiate or intensify statins or antihypertensive medication. Centers for Medicare & Medicaid Services did not pay for CVD risk reduction for medium-risk enrollees, but initiation or intensification rates for these enrollees were also higher in the intervention vs control groups (12 668 [27.9%] vs 7544 [24.8%]; adjusted difference in percentage points, 3.1; 95% CI, 1.9-4.3; P < .001). Among high-risk enrollees with clinical data approximately 1 year after enrollment, LDL cholesterol level was slightly lower in the intervention vs control groups (mean [SD], 89 [31.8] vs 91 [32.1] mg/dL; adjusted difference in percentage points, -1.8; 95% CI, -2.9 to -0.6; P = .002), as was systolic blood pressure (mean [SD], 133 [15.7] vs 135 [16.4] mm Hg; adjusted difference in percentage points, -1.7; 95% CI, -2.8 to -0.6; P = .003). CONCLUSIONS AND RELEVANCE: In this study, a pay-for-performance model led to modest increases in the use of CVD medications in a range of organizations, despite high medication use at baseline.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Peterson GG, Pu J, Magid DJ, et al. Effect of the Million Hearts Cardiovascular Disease Risk Reduction Model on Initiating and Intensifying Medications: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2021. PMID: 34076665. doi:10.1001/jamacardio.2021.1565

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。